| Jodilyn Jelsema, MD | |
|
500 N Montgomery Ave, Sheffield, AL 35660-2861 | |
| (256) 386-5504 | |
| Not Available |
| Full Name | Jodilyn Jelsema |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 500 N Montgomery Ave, Sheffield, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518195460 | NPI | - | NPPES |
| Entity Name | Shoals Primary Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326373861 PECOS PAC ID: 1557406246 Enrollment ID: O20100305000357 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.
Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.
› Verified 1 days ago
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210224000756 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.
Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jodilyn Jelsema, MD 6216 66th St Apt 519, Lubbock, TX 79424-5941 Ph: (616) 706-3072 | Jodilyn Jelsema, MD 500 N Montgomery Ave, Sheffield, AL 35660-2861 Ph: (256) 386-5504 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.
Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.
› Verified 1 days ago